This article describes a very exciting new immunodiagnostic tool, potentially allow the discovery of new biomarkers for the pathogenesis of immunologic disorders and in monitoring therapy, said Andy Saxon the Editor – in – Chief of the CIS journal.
The presentations on the discovery, in vitro antiviral activity is concentrated, resistance profile, pharmacokinetics and mechanism of action of GL60667 , a potent non-nucleoside inhibitor of HCV NS5B polymerase. The presentations included studies both Genelabs and Novartis scientists in connection with the licensing and research collaboration conducted began in June 2006 between the Company and covers Genelabs non-nucleoside HCV polymerase inhibitors. GL60667 detected one of a number of non-nucleoside HCV polymerase inhibitors by Genelabs.Has the student Career Fair raises the afternoons of starting 13 students biomedical engineering, biotechnology and different health science specific careers, comply meet prospective employers in these fields , the business discussion full-time placement. And the summer employment possibilities.